Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 352.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lakefront Biotherapeutics NV was 352.00% per year. The lowest was -109.10% per year. And the median was -19.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lakefront Biotherapeutics NV 3-Year EBITDA Growth Rate Related Terms
LKFT vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 352.00% mean?
Lakefront Biotherapeutics NV (LKFT) has a 3-Year EBITDA Growth Rate of 352.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lakefront Biotherapeutics NV and its competitors. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #3 out of 1127 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Lakefront Biotherapeutics NV's 3-Year EBITDA Growth Rate too high?
Lakefront Biotherapeutics NV's current 3-Year EBITDA Growth Rate is 352.00%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Lakefront Biotherapeutics NV's value of 352.00% is 2311% above this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #3 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #3 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Lakefront Biotherapeutics NV in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Lakefront Biotherapeutics NV's value of 352.00% is 2311% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current 3-Year EBITDA Growth Rate of 352.00% is 2311% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current 3-Year EBITDA Growth Rate is 352.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is $115.40, compared to a current price of $28.49 — trading 75.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 352.00% and 2311% above the Biotechnology industry median of 14.60. Lakefront Biotherapeutics NV's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (LKFT), the current 3-Year EBITDA Growth Rate is 352.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.49 is trading 75.3% below its estimated GF Value™ of $115.40.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for LKFT:
3-Year EBITDA Growth Rate: 352.00%
GF Value™: $115.40 vs. price of $28.49 (75.3% below fair value)
Industry Position: 2311% above the Biotechnology median (#3 of 1127)
No single metric tells the full story. See the LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
57GF Score
Get the complete analysis for LKFT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LKFT has been successfully added to your 
